Sun Pharmaceutical Industries Ltd. Q1 FY2026 results: revenue ₹13,851 crore, up 9.5% on the year
Sun Pharmaceutical Industries Ltd. (SUNPHARMA) reported consolidated revenue from operations of ₹13,851 crore for Q1 FY2026, the quarter ended 30 June 2025, up 9.5% on the same quarter a year earlier. Profit after tax was ₹2,293 crore, down 19.8% on the year, and earnings per share ₹9.50. The figures are the company's own, from the un-audited results it filed with NSE on 31 July 2025.
The quarter, against the one before and a year earlier
| Line | Q1 FY2026 | Q4 FY2025 | Q1 FY2025 | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 13,851 | 12,959 | 12,653 | +9.5% |
| Other income | 464 | 613 | 533 | -12.8% |
| Total income | 14,316 | 13,572 | 13,185 | +8.6% |
| Cost of materials consumed | 1,772 | 1,845 | 1,557 | +13.8% |
| Purchases of stock-in-trade | 1,048 | 1,037 | 997 | +5.1% |
| Changes in inventories | -5 | -245 | 121 | n/a |
| Employee benefit expense | 2,802 | 2,489 | 2,455 | +14.1% |
| Finance costs | 75 | 49 | 62 | +21.5% |
| Depreciation, depletion and amortisation | 701 | 664 | 655 | +6.9% |
| Other expenses | 4,162 | 4,408 | 3,915 | +6.3% |
| Total expenses | 10,325 | 9,956 | 9,762 | +5.8% |
| Profit before exceptional items and tax | 3,991 | 3,616 | 3,424 | +16.6% |
| Exceptional items | -818 | -362 | 0 | n/a |
| Profit before tax | 3,173 | 3,254 | 3,424 | -7.3% |
| Current tax | 870 | 1,094 | 552 | +57.6% |
| Deferred tax | 0 | 0 | 0 | n/a |
| Total tax | 870 | 1,094 | 552 | +57.6% |
| Profit after tax | 2,293 | 2,154 | 2,861 | -19.8% |
| Attributable to owners of the parent | 2,279 | 2,150 | 2,836 | -19.6% |
| Other comprehensive income | 127 | 335 | 41 | +207.9% |
| Total comprehensive income | 2,420 | 2,489 | 2,902 | -16.6% |
| EPS, basic | ₹9.50 | ₹9.00 | ₹11.80 | -19.5% |
| EPS, diluted | ₹9.50 | ₹9.00 | ₹11.80 | -19.5% |
₹ crore except per share.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,192 | 12,381 | 11,983 | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Expenses | 9,695 | 9,561 | 9,672 | 9,762 | 10,048 | 10,349 | 9,956 | 10,325 | 10,781 | 11,383 | 11,519 | 11,721 |
| Operating profit | 3,179 | 3,477 | 3,035 | 3,608 | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | 4,418 |
| OPM % | 26% | 28% | 25% | 29% | 30% | 29% | 29% | 31% | 31% | 32% | 27% | 29% |
| Other income | 294 | 250 | 606 | 533 | 354 | 466 | 613 | 464 | 470 | 579 | 458 | 724 |
| Interest | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 |
| Depreciation | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 |
| Exceptional items | 0 | -70 | -102 | 0 | 0 | -316 | -362 | -818 | 0 | -489 | 0 | -204 |
| Profit before tax | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 |
| Tax % | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% |
| Net profit | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| EPS in ₹ | ₹9.90 | ₹10.50 | ₹11.10 | ₹11.80 | ₹12.70 | ₹12.10 | ₹9.00 | ₹9.50 | ₹13.00 | ₹14.00 | ₹11.30 | ₹12.10 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.
Source
Un-audited consolidated results for the quarter ended 30 June 2025, filed with NSE on 31 July 2025: the result statement. All of Sun Pharmaceutical Industries Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.